Our Story

2009

Founded in 2009, Hetero Biopharma ushered in a new era of biopharmaceutical development. Driven by a robust R&D ecosystem, the company emerged as a trusted manufacturer of affordable, high-quality medicines, expanding access to healthcare for patients around the world.

Our Story

2011

The state-of-the-art manufacturing facility, established in 2011, was outfitted with the latest technologies and advanced equipment, ensuring the manufacture of safe, effective, and high-quality medicines that meet global standards.

Our Story

2014

Our biosimilar journey began with the launch of Derise® (Darbepoetin alfa), a biosimilar to Aranesp®. As the second company globally to introduce a Darbepoetin alfa biosimilar, this milestone marked the beginning of our biosimilars journey, expanding access to treatment for patients with chronic kidney disease-related and chemotherapy-induced anaemia.

Our Story

2015

We launched our second biosimilar and first monoclonal antibody, Rilast® (Rituximab), a biosimilar to MabThera®. This milestone strengthened our biosimilars portfolio and expanded access to treatment for patients with non-Hodgkin lymphoma, chronic lymphocytic leukaemia, and rheumatoid arthritis.

Our Story

2016

Brought to market Bevaas® (Bevacizumab), a biosimilar to Avastin®, expanding treatment options for patients with colorectal, lung, ovarian, cervical, and kidney cancers. We also received regulatory approval for our manufacturing facility from a PIC/S member country, reinforcing our commitment to global quality and compliance standards.

Our Story

2017

Introduced Pamera® (Adalimumab Solution for Injection in a pre-filled syringe [PFS]), a biosimilar to Humira®, expanding treatment options for patients with rheumatoid arthritis, psoriatic arthritis, ankylosing spondylitis, psoriasis, and inflammatory bowel disease.

During the same year, we commissioned an additional manufacturing unit, further strengthening our manufacturing capacity and scalability.

Our Story

2022

Expanded our oncology portfolio with Sezuma® (Trastuzumab Lyophilized Powder for Injection), a biosimilar to Herceptin®, improving access to biologic therapy for patients with HER2-positive breast and metastatic gastric cancers. This reinforced our expertise in the development and manufacture of complex oncology biologics portfolio and improving patient access to advanced biologic therapies.

Our Story

2023

The launch of TNKPLASE (Tenecteplase), a biosimilar to Metalyse®, expanded access to timely thrombolytic therapy for patients experiencing acute myocardial infarction, while Pegalsa® (Pegylated Asparaginase), a biosimilar to Oncaspar®, enhanced access to a vital treatment for patients with acute lymphoblastic leukemia (ALL).

Our Story

2024

The launch of Aspalsa® (L-Asparaginase), a biosimilar to Elspar®, marked a significant step in strengthening our oncology biologics portfolio and providing cost-effective, high-quality cancer therapies.

Our Story

2025

Denotec™ (Denosumab), a biosimilar to Xgeva®, represented a key advancement in our complex biologics journey, supporting patients with bone metastases from solid tumors and multiple myeloma, while strengthening our capabilities in monoclonal antibody development and manufacturing.

Enabling a future
where hope and
access thrive

Hetero Biopharma Expertise

Monoclonal antibodies (mAbs)

Recombinant proteins

Antibody Drug Conjugates (ADC)

Vaccines

Cell
therapies

Gene
therapies

Single-use solutions

Small molecule products

Monoclonal antibodies (mAbs)

Recombinant proteins

Antibody Drug Conjugates (ADC)

Vaccines

Cell
therapies

Gene
therapies

Single-use solutions

Small molecule products

Power of Biosimilars

Our
Biosimilars

The Biologics or biosimilars are
produced using a unique cell line and
a proprietary process that varies
from one manufacturer to another.

Our state-of-the-art manufacturing facilities are designed with advanced technologies and operate in accordance with global quality, cGMP, and PIC/S standards. Supported by PIC/S accreditation and Indian regulatory approvals, they exemplify our commitment to consistently delivering safe, effective, and high-quality biosimilar products.

Our Core
Competencies

The year 2009, Hetero’s vertically integrated
biologics venture began with a focus on
key biosimilars through its Hetero
Research Foundation (HRF).

Our Insignia

high quality human biotechnology

Inspired by the powerful symbolism of DNA and an hourglass, the Hetero Biopharma insignia embodies our dedication to ‘preserving life’ and ‘valuing time’. It reflects our mission to deliver high-quality biopharmaceutical innovations and bring them to patients faster, enabling broader access to advanced therapies and helping build a healthier world for generations to come.

The colours Orange and Deep Yellow are a representation of the 'day break' and signify hope and life. The Grey colour signifies our intent to apply knowledge and expertise for better outcomes eventually amounting to a healthier world, a healthier tomorrow.